Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 21: 104-108, 1975;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, D.
Right arrow Articles by Solomons, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, D.
Right arrow Articles by Solomons, C. C.

Clinical Chemistry, Vol 21, 104-108, Copyright © 1975 by the American Association for Clinical Chemistry

Increased Inorganic Serum Pyrophosphate in Serum and Urine of Patients with Osteogenesis Imperfecta

Donald Armstrong 1, Dale VanWormer 2, and Clive C. Solomons 3

1 Department of Neurology, University of Colorado Medical Center, 4200 East 9th Ave., Denver, Colo. 80220.Department of Pathology and Clinical Chemistry, Hillcrest Medical Center, Tulsa, Okla. 74104.
2 Department of Pathology and Clinical Chemistry, Hillcrest Medical Center, Tulsa, Okla. 74104.
3 Department of Pediatrics, University of Colorado Medical Center, Denver, Colo. 80220.

Inorganic pyrophosphate can be accurately determined in 2 to 4 ml of serum or urine by an ion-exchange method. Pyrophosphate degradation by serum alkaline phosphatase and pyrophosphatase is stopped by adding to the serum 0.1 mmol of dithiothreitol (Cleland's reagent) per liter. This method is suitable for screening large numbers of patients. All of the patients studied who had classical symptoms of active osteogenesis imperfecta also had abnormally high concentrations of pyrophosphate in their serum. Of this group, 62% excreted increased amounts of pyrophosphates in their urine. Seven adults with inactive osteogenesis imperfecta had normal concentrations of inorganic pyrophosphate in their serum, but their urinary excretion of pyrophosphate was abnormally great. Patients undergoing therapy with magnesium oxide or calcitonin had normal values for serum and urine pyrophosphate. Determination of inorganic pyrophosphate concentrations in serum may be helpful in studying the progress of this disease and in monitoring therapy.


Key Words: screening • phosphatase inhibition • inherited disorder • normal values • monitoring of therapy

Submitted on July 13, 1974
Accepted on October 16, 1974






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by the American Association for Clinical Chemistry.